IKT vs. INAB, OKYO, NKGN, BCLI, CYTH, QNCX, ESLA, ACHL, SRZN, and INKT
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include IN8bio (INAB), OKYO Pharma (OKYO), NKGen Biotech (NKGN), Brainstorm Cell Therapeutics (BCLI), Cyclo Therapeutics (CYTH), Quince Therapeutics (QNCX), Estrella Immunopharma (ESLA), Achilles Therapeutics (ACHL), Surrozen (SRZN), and MiNK Therapeutics (INKT). These companies are all part of the "biological products, except diagnostic" industry.
IN8bio (NASDAQ:INAB) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
IN8bio currently has a consensus price target of $10.00, suggesting a potential upside of 890.10%. Inhibikase Therapeutics has a consensus price target of $23.00, suggesting a potential upside of 1,170.72%. Given IN8bio's higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than IN8bio.
In the previous week, IN8bio had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 8 mentions for IN8bio and 6 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.08 beat IN8bio's score of -0.65 indicating that IN8bio is being referred to more favorably in the media.
92.1% of IN8bio shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by company insiders. Comparatively, 16.0% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
IN8bio has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
IN8bio received 14 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Inhibikase Therapeutics an outperform vote while only 68.97% of users gave IN8bio an outperform vote.
Inhibikase Therapeutics has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -5,886.15%. IN8bio's return on equity of -147.03% beat Inhibikase Therapeutics' return on equity.
Summary
IN8bio and Inhibikase Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
